The myelodysplastic syndromes (MDS) are associated with a diverse set of acquired somatic genetic abnormalities. Bone marrow karyotyping provides important diagnostic and prognostic information and should be attempted in all patients who are suspected of having MDS. Fluorescent in situ hybridization (FISH) studies on blood or marrow may also be valuable in selected cases, such as patients who may have 5q-syndrome or those who have undergone hematopoietic stem cell transplantation. The MDS-associated cytogenetic abnormalities that have been defined by karyotyping and FISH studies have already contributed substantially to our current understanding of the biology of malignant myeloid disorders, but the pathobiological meaning of common, recurrent chromosomal lesions such as del(5q), del(20q), and monosomy 7 is still unknown. The great diversity of the cytogenetic findings described in MDS highlights the molecular heterogeneity of this cluster of diseases. We review the common and pathophysiologically interesting genetic abnormalities associated with MDS, focusing on the clinical utility of conventional cytogenetic assays and selected FISH studies. In addition, we discuss a series of well-defined MDS-associated point mutations and outline the potential for further insights from newer techniques such as global gene expression profiling and array-based comparative genomic hybridization. 
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DISEASE SYNOPSIS
The term myelodysplastic syndromes (MDS) describes a diverse group of acquired hematopoietic stem cell malignancies unified by a common functional consequenceineffective production of mature blood cells. 1, 2 In MDS, cytologic dysplasia of blood and marrow cells is associated with functional defects in neutrophils and platelets, which contribute to infection and bleeding complications, respectively, even in the absence of substantial deficits in blood cell production. The variable risk of progression to acute myeloid leukemia (AML) that is characteristic of MDS appears to be driven by somatic genomic instability and epigenetic genomic modification. Evidence for this includes allelic imbalance arising from structural or numerical chromosome aberrations, defects in DNA repair, 3, 4 and linkage to genotoxic exposures including alkylating agents, topoisomerase II inhibitors, environmental poisons, or radiation. 1, 2 This overview highlights the genetic and molecular abnormalities in adults with MDS, methods to detect these abnormalities, and their potential importance for diagnosis, prognosis, and therapy ( Table 1) . The inherited and acquired MDS in pediatric patients display genetic and clinical features distinct from those in adults 5 and will not be addressed in this review.
Most adult patients with MDS present to their physicians with signs and symptoms related to anemia or pancytopenia, or their illness is discovered incidentally when a blood cell count is performed for another purpose. The diagnosis of MDS is established from the characteristic appearance of a bone marrow aspirate, but in some cases cytologic features may be subtle, creating challenges with respect to excluding nonneoplastic causes of cellular dysplasia. In such cases, genetic testing provides an alternative means of diagnosis confirmation and offers further insight into prognosis and management considerations.
The 1976 French-American-British (FAB) Co-operative Group classification scheme for MDS, revised and expanded in 1982, provided the first widely used tool for disease classification and prognostication. 6 The FAB classification is based on the proportion of immature blast cells in the blood and marrow and on the presence or absence of ringed sideroblasts or peripheral blood monocytosis. In 1999, a group of hematopathologists and clinicians operating under the auspices of the World Health Organization (WHO) created a new classification system for MDS based on the FAB framework but incorporated newer morphologic insights and, to a more limited extent, cytogenetic findings (Table 2) . 7, 8 For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings. For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings. Mutations result in loss of function of tumor Mutated in 5%-10% of patients with MDS, more suppressor p53, "the guardian of the genome"-commonly mutated in secondary MDS, may be an essential regulator of cell cycle, specifically associated with progression to AML transition from G0 to G1 NRAS Constitutively activates oncogene by preventing Codon 12 mutation is most common in MDS and normal GTP recycling, resulting in uncontrolled found in 10%-15% of cases; acquisition of mutation growth signalling commonly associated with progression to AML
FLT3
Internal tandem duplications of juxtamembrane domain Found in up to 10% of MDS cases; acquisition of or point mutations result in constitutive activation mutation commonly associated with progression to and uncontrolled growth signalling AML RUNX1/AML1 Point mutations result in loss of normal trans-activating Most common point mutation described to date in potential of the key RUNX1 core-binding factor MDS-in up to 25% of cases; associated with high subunit and consequent changes in gene expression risk of progression to AML, previous radiation exposure, and chromosome 7 abnormalities c-FMS Mutations constitutively activate the receptor for Occasionally associated with CMML colony-stimulating factor 1, a cytokine that controls the production, differentiation, and function of monocyte-macrophages PTPN11
Mutations alter function of the SHP2 that has diverse Rarely associated with CMML or other MDS, roles in cell signalling, including modulation of commonly associated with JMML PDGFR phosphorylation and STAT activity ATRX Point mutations result in loss of function of ATRX Acquired α-thalassemia; no apparent effect on multiprotein complex with consequent changes in proliferative potential of thalassemic clone gene expression, including down-regulation of α globin cluster, probably by epigenetic mechanisms *Gene expression changes that have been documented via microarray analyses are not included because their relevance has not yet been established. AML = acute myeloid leukemia; ATRX = α-thalassemia mental retardation X-linked; c-FMS = McDonough feline sarcoma virus oncogene homolog; CMML = chronic myelomonocytic leukemia; FLT3 = fms-related tyrosine kinase 3; GTP = guanosine triphosphate; IPSS = International Prognostic Scoring System; JMML = juvenile myelomonocytic leukemia; MDS = myelodysplastic syndromes; NRAS = neuroblastoma viral rat sarcoma oncogene homolog; PDGFR = platelet-derived growth factor receptor; PTPN11 = protein tyrosine phosphatase, nonreceptor type 11; RUNX1 = runt-related transcription factor 1; SHP2 = SH2 domain-containing protein tyrosine phosphatase 2; STAT = signal transducer and activator of transcription; TP53 = tumor protein p53; WHO = World Health Organization. 7 
TREATMENT OVERVIEW
The current spectrum of treatments for MDS is limited; however, encouraging results with novel agents in development offer promise. 9 For most patients, management is primarily supportive, relying on transfusions and antimicrobials as dictated by symptoms and infectious complications. Select patients will experience hematologic improvement with the use of recombinant hematopoietic growth factors, including erythropoietin and granulocyte colonystimulating factor. 10, 11 With the advent of new therapeutic alternatives, the management strategy for many patients has shifted from sole reliance on supportive measures to more active intervention. The Food and Drug Administration recently approved the first agent with an indication for MDS, 5-azacitidine (Vidaza, Pharmion Corporation, Boulder, Colo), an injectable nucleoside analogue that covalently incorporates into DNA and depletes DNA methyltransferases to promote genome hypomethylation. This may contribute to reactivation of methylation-silenced tumor suppressor genes. In a national cooperative group openlabel randomized trial of MDS, 5-azacitidine treatment delayed leukemic transformation and reduced the risk of AML progression or death. 12 Most other noninvestigational agents offer limited benefit for the general population with MDS but are reasonable considerations for select individuals. For example, thalidomide, when administered at low doses for an extended schedule, may restore erythropoiesis in some patients; however, neurotoxicity and other adverse effects limit dose escalation and prolonged drug administration, particularly in elderly individuals. 13 Antithymocyte globulin and other immunosuppressants may be effective in patients with hematopoietic inhibitory immune effectors; such patients may be identified through predictive modelling. [14] [15] [16] Older agents such as androgens and pyridoxine are usually ineffective. 17, 18 Aggressive chemotherapy similar to that used for acute leukemia should be reserved for clinical trials; it is rarely curative. 19 Younger patients are often candidates for curative strategies such as allogeneic hematopoietic stem cell transplantation; however, mortality and morbidity remain high, even in experienced and specialized centers. 20 Autologous transplantation may benefit selected patients without an allogeneic donor, but the potential benefit of this approach appears limited to younger patients. 21 Unfortunately, the vast majority of patients with MDS are not candidates for stem cell transplantation with conventional ablative conditioning regimens because the median age at the time of diagnosis is in the seventh decade of life, and comorbidities are common. Reduced-intensity conditioning or nonmyeloablative approaches promise to expand the upper age limit of candidates for stem cell therapy. 20, 22 The optimal timing of transplantation is a subject of active investigation.
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Iron overload remains a clinical challenge, especially in patients who require frequent red blood cell transfusions, emphasizing the need for iron chelation therapy for patients with otherwise favorable prognostic features in whom extended survival is expected. Given the paucity of diseasealtering therapies for MDS, clinical trial enrollment is paramount to advance the field. At least 2 agents in clinical development, the immunomodulatory drug lenalidomide (CC-5013, Revlimid; Celgene Corporation, Warren, NJ) and the demethylating agent decitabine (Dacogen, Supergen, Inc, Dublin, Calif), have shown promising preliminary results, and Food and Drug Administration review should occur in the months ahead.
24,25

STANDARD CYTOGENETIC STUDIES AND TEST RATIONALE
At present, the most widely available genetic test applied in the evaluation of patients with MDS is cytogenetic analysis by conventional metaphase karyotyping. Karyotyping has been applied widely since the 1970s, and the method for performing these assays and their limitations have been reviewed recently. 26, 27 Briefly, standard cytogenetic assays involve light-microscopic visualization of metaphase chromosomes prepared by (1) inducing the cells of interest to divide, (2) arresting their division at the appropriate mitotic stage with colchicine, (3) lysing the cells, and (4) Giemsa staining of the chromosome spread to resolve the chromosome size and banding pattern ( Figure 1 ).
In diagnostically ambiguous cases, an abnormal karyotype can provide important evidence to support the presence of a clonal, neoplastic process. 28 Additionally, cytogenetic studies provide important prognostication discrimination. The 1997 International Prognostic Scoring System (IPSS) for MDS, based on a review of 816 patients with "primary" MDS (ie, no history of treatment with chemotherapy or radiotherapy), incorporates 3 elements with independent prognostic power into the staging algorithm: (1) the proportion of myeloblasts in the patient's marrow, (2) the number of blood cell lineage deficits, and (3) the type of chromosomal abnormality present. 29 Using these 3 elements, a score generated by the IPSS algorithm reproducibly classifies patients with MDS into a highest-risk group with a median survival of only 0.4 years, a pair of intermediate-risk groups, and a lowest-risk group with a median survival of 5.7 years overall, 11.8 years for patients 60 years of age or younger. The IPSS algorithm has been validated independently.
30,31
The IPSS clusters the varied chromosomal abnormalities observed in MDS into 3 risk groups: poor risk 
29
The IPSS is an important clinical tool and maintains prognostic validity for both standard therapy and allogeneic stem cell transplantation. In one analysis, patients with a poor-risk cytogenetic pattern had a 3.5-fold greater risk of relapse after stem cell transplantation than did patients with a good-risk karyotype. 33 Similar findings have been reported for patients treated with intensive antileukemic chemotherapy, with or without subsequent transplantation. 19, 34 Not surprisingly, acquisition of higher-risk IPSS cytogenetic abnormalities during the course of disease adversely impacts survival because of leukemic evolution or cytopenic complications.
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COMMON CYTOGENETIC ABNORMALITIES IN PRIMARY MDS
Although not specific for MDS, the recurrent chromosomal abnormalities defined by the IPSS (ie, -7/del(7q), del(5q), del(20q), and -Y) are among the most common detected in MDS. Overall, 40% to 50% of patients with primary MDS present with 1 or more clonal karyotypic abnormalities, whereas in those with secondary MDS (ie, after therapeutic chemotherapy or radiotherapy for an unrelated condition), the proportion of patients with an abnormal karyotype exceeds 80%.
2,28,31,36-38 The relative frequency of specific cytogenetic abnormalities in primary MDS ranges from as high as 30% for del(5q)-either as an isolated anomaly (10%) or as part of a more complex karyotype (20%)-to 20% for trisomy 8 and 15% for monosomy 7. 39 Numerous other recurrent abnormalities have been observed, but each accounts for less than 10% of cases of primary MDS.
CYTOGENETIC ABNORMALITIES IN SECONDARY MDS
The distribution of chromosome abnormalities is skewed in treatment-related MDS, in which structural or numerical deletions of chromosome 7 (40%) and chromosome 5 (40%) predominate. 36, 39 Together, abnormalities of chromosome 5 and 7 account for approximately 75% of karyotypic abnormalities in secondary MDS, 36 whereas all other karyotypic abnormalities occur with a frequency of 10% or less. 39 In addition to the higher frequency of abnormal karyotypes, secondary MDS displays a disproportionate percentage of IPSS poor-risk abnormalities, and as with primary MDS these are associated with an unfavorable prognosis. This cytogenetic pattern is frequently linked to and believed to be induced by prior treatment with alkylating antineoplastics.
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The IPSS good-risk abnormalities occur with sufficient rarity in secondary MDS to raise suspicion that such cases instead represent de novo and treatment-unrelated MDS. Nevertheless, single-institution studies indicate that patients with such karyotypes fare better than their counterparts with secondary disease who have poor-risk karyotype abnormalities. 36 When the spectrum of abnormalities associated with primary and secondary MDS is compared, secondary forms more commonly exhibit monosomy 5, monosomy 7, and der(17p) aberrations, whereas in primary MDS, isolated del(5q) and normal karyotype predominate. 39 Treatment with topoisomerase II inhibitors has been linked to chromosome 3q inversions or translocations and to balanced translocations involving 11q23 deregulating the MLL gene.
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OTHER RECURRENT CYTOGENETIC ABNORMALITIES IN MDS Numerous chromosomal abnormalities occur with moderate frequency (ie, 1%-10%) in MDS; however, because of overall low prevalence, their prognostic relevance remains undefined. Limited case series have linked trisomy 8 with an increased risk of AML transformation, and abnormalities of chromosome 1q, 3q21, and 11q23 with an overall inferior survival. 30, 31, 40, 42 In contrast, del(12p) as a sole abnormality has been associated with an indolent disease course. 31 The prognostic relevance of less common (ie, <1% of cases) yet recurrent chromosomal abnormalities remains uncertain. [43] [44] [45] [46] [47] Although multiple independent and karyotypically discordant clones may be identified in se- (2) 48 (6) 489 (60) 16 (2) 74 (9) 38 (5) 14 (2) 10 (1) 15 (2) 66 (8) 29 ( 
GENETIC TESTING IN THE MYELODYSPLASTIC SYNDROMES
The karyotypic diversity included in the Mitelman database illustrates that the diagnostic category of MDS contains disorders that phenotypically overlap yet have a molecularly distinct pathobiology. Although the IPSS has proved its clinical usefulness, the IPSS intermediate-risk category includes potentially hundreds of chromosomal abnormalities, suggesting that further refinement of the algorithm will be possible. As therapy for MDS improves, the prognosis associated with particular karyotypes may change. By analogy, before the introduction of retinoic acid therapy for acute promyelocytic leukemia (APL) in the 1980s, the classic t(15;17) APL-associated chromosomal translocation was regarded as an intermediate-risk leukemia karyotype, but with modern drug therapy APL is among the most curable AML subtypes. 50 Although balanced favorable translocations such as t(15;17) and t(8;21) are relatively common in AML, they are rare in MDS in which deletions and numerical chromosomal abnormalities predominate. 2, 29, 51 Given the responsiveness to conventional leukemia chemotherapy, the WHO categorizes 4 specific rearrangements involving core-binding factor transcriptional repressors [ie, t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22), and t(15;17)(q22;q12)] as AML, regardless of the bone marrow myeloblast percentage. 7, 8 For those exceptional cases that harbor such karyotypic abnormalities with a low myeloblast burden, it remains unclear whether AML therapy impacts survival as it does in more typical AML. 52, 53 CLONAL CYTOGENETIC ABNORMALITIES IN THE ABSENCE OF MORPHOLOGIC EVIDENCE OF MYELODYSPLASIA In selected cases in which marrow aspiration is performed for evaluation of cytopenias, routine staging, or follow-up of another malignancy, clonal karyotypic abnormalities may be identified in the absence of cytologic dysplasia that would support a diagnosis of MDS. 54 The constitutional karyotype in nonhematopoietic tissue in such cases has been normal, confirming an acquired somatic cytogenetic abnormality. This constellation of findings may represent a forme fruste of MDS, 54 evidenced by an increased risk of leukemic transformation and subsequent cytopenic mortality. 54 These uncommon cases emphasize the importance of cytogenetic evaluation in the investigation of unexplained cytopenias, even in the absence of overt morphologic evidence of MDS.
RELEVANCE OF ALL ABNORMAL VS ABNORMAL-NORMAL CYTOGENETIC PATTERN
When a chromosomal abnormality is detected by conventional cytogenetics, the abnormality may be present in all examined metaphases (all abnormal [AA]) or in only a fraction of the metaphases (sometimes termed abnormalnormal [AN] ). 28, 35 The AA pattern correlates with higherrisk MDS subtypes identified by the FAB MDS pathologic classification, 6 and patients with AA have a poorer overall survival than those with AN.
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The favorable modifying effect of increasing proportions of normal metaphases has precedent in other hematologic malignancies. The clinical usefulness of the reduction in the number of abnormal metaphases with therapy is perhaps best illustrated by chronic myeloid leukemia (CML). In CML, a "major cytogenetic response" represents an important therapeutic goal because patients who achieve a complete cytogenetic remission experience a superior progression-free survival compared with those patients with persistence of any proportion of metaphases bearing the Philadelphia chromosome. [55] [56] [57] By analogy, an international working group that created standardized response criteria for clinical trials of MDS included reductions in the number of abnormal metaphases as one of these response criteria, although the clinical importance of this measurement had not yet been formally established in MDS. 58 Evidence from recent clinical trials testing new potentially disease-modifying agents supports this notion. In a large phase 2 study of intravenous decitabine in higher-risk MDS, 31% of patients achieved a complete cytogenetic remission, with a corresponding reduction in the relative risk of death (0.38 compared with those in whom the abnormal clone persisted). 59 These preliminary data suggest that a cytogenetic response may also be an important disease-modifying marker in MDS.
BONE MARROW VS PERIPHERAL BLOOD CYTOGENETIC STUDIES IN MDS
Most chromosomal studies in patients with MDS are performed on bone marrow cells. Peripheral blood karyotyping has a higher failure rate than marrow studies and rarely adds useful information beyond that available from the marrow study. 37 Unlike CML, in which tracking the proportion of cells containing the Philadelphia chromosome or its molecular equivalent is critical for monitoring therapy and the results may prompt management changes in the absence of the need for an additional marrow aspiration, there is currently little compelling clinical indication for frequent assessment of chromosomal status in MDS. In special situations in which chromosomal information is desirable but a marrow examination is not required, such as measuring donor/host chimerism after stem cell transplantation, fluorescent in situ hybridization (FISH) assays (discussed subsequently) may be preferable.
INDICATIONS FOR CYTOGENETIC TESTING IN MDS
When should a karyotype be obtained for patients with MDS? Given the importance of the IPSS risk assessment, a chromosomal study is an essential part of the initial evaluation (Table 3) . Acquisition of new chromosome abnormalities (ie, cytogenetic evolution) portends disease progression and therefore justifies cytogenetic evaluation in the routine management of MDS. Some clinicians obtain a cytogenetic study every time a marrow aspiration is performed during the care of patients with MDS, whereas others obtain such studies only in relationship to planned therapeutic trials or when there are signs of a change in the patient's condition. No evidence base exists to help guide this practice, and therefore such decisions are best left to the discretion of the individual treating clinician. After transplantation, karyotypic analysis may not only help in early determination of relapse (ie, before morphologic evidence of recurrent disease is present) but also is useful in assessment of donor-host chimerism in the case of sex mismatches between marrow donor and host.
MOLECULAR CYTOGENETICS IN MDS
Delineating the pathogenetically relevant alterations in MDS at the gene level, even for recurrent cytogenetic abnormalities, has proved challenging. The so-called 5q-syndrome is perhaps the best example of the difficulties faced. First delineated in the early 1970s, 5q-syndrome is a form of refractory anemia characterized by female predominance, atypical megakaryocytes, erythroid hypoplasia with red blood cell transfusion dependence, and a low risk of leukemic transformation with prolonged survival. These clinical and pathological features are consistently associated with an isolated interstitial deletion of the long arm of chromosome 5 that involves 5q31.1.
60,61 Although earlier reports varied in the definition of the 5q-syndrome, general consensus is that this description should be limited to patients with an isolated 5q31.1 interstitial deletion in the absence of other cytogenetic abnormalities, a low bone marrow blast percentage, and no history of genotoxic therapy. 62 The WHO's most recent classification schema for malignant hematopoietic diseases formally recognizes 5q-syndrome as a discrete entity within the general category of MDS. 7 Although no other specific MDS-associated chromosome aberration has been recognized by the WHO as a distinct pathologic and clinical syndrome, other recurrent chromosome abnormalities have been linked with specific disease features. For example, isolated isochromosome 17q may be associated with myeloproliferative features and poor response to therapy, 63 isodicentric X has been linked to iron overload in older women, 64 trisomy 8 displays a male predominance, [65] [66] [67] and inv(3)(q21q26.2) is associated with thrombocytosis with megakaryocytic dysplasia and poor therapeutic response.
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Boultwood and colleagues at Oxford have carefully defined the commonly deleted region (CDR) in patients with 5q-syndrome using FISH and other molecular mapping techniques, and they have cloned several novel genes in the process. [69] [70] [71] [72] The defined CDR spans 1.5 megabase pairs at 5q31.1. 71 This CDR is relatively gene rich, containing no less than 40 discrete genes, 33 of which are expressed in early hematopoietic cells. 71 Several of these genes are members of the interleukin family or have other potential promoting roles in hematopoiesis. A number of genes within the CDR are not well characterized, and their function is as yet unknown. To date, systematic sequencing of these genes in patients with 5q-syndrome has not revealed pathogenetic mutations, and thus it is now believed that the pathophysiology of 5q-syndrome may relate to gene dosage rather than mutational gene deregulation in the CDR. 
GENETIC TESTING IN THE MYELODYSPLASTIC SYNDROMES
Other groups are investigating additional recurrent MDS-associated chromosome abnormalities in an attempt to identify critical gene targets, including del(20q), trisomy 8, del(7q), and del(9q). In selected cases, study of patients with parallel inherited disorders may provide insight. For example, patients with constitutional trisomy 8 mosaicism appear to have a high risk of developing myeloid malignancies including MDS and leukemia. 73 Chromosome 7 may be particularly challenging because there are multiple CDRs, including 7q22 and several in the region 7q31-7q35. [74] [75] [76] Perhaps the most important molecular cytogenetic discovery in recent years with immediate therapeutic implication is the reciprocal chromosome translocation involving chromosome 5q33, where the gene encoding the β subunit of the platelet-derived growth factor receptor (PDGFR-β) is located. Although a number of chromosomes and genes may partner with 5q33, the clinical phenotype is distinct and is now recognized by the WHO classification as chronic myelomonocytic leukemia (CMML) with eosinophilia (CMML-Eos). (The WHO classification removed all CMML subtypes from the MDS group, where they had been placed in the widely used 1982 FAB MDS classification, and placed them in a separate myelodysplastic/ myeloproliferative overlap category. This was done because patients with CMML frequently exhibit prominent myeloproliferative features, unlike patients with other subtypes of MDS. 6, 7, 77 ) The CMML-Eos phenotype arises from the generation of novel fusion transcripts with constitutive activation of the PDGF-β receptor tyrosine kinase. [78] [79] [80] [81] [82] Transgenic mouse models have shown that these novel receptor tyrosine kinase fusion genes are singularly responsible for the generation of these myelodysplastic/myeloproliferative disorders and are selectively responsive to PDGFR kinase inhibitors such as imatinib (Gleevec, Novartis, Basel, Switzerland). 79, 83, 84 Several patients with CMML-Eos have been reported to achieve rapid hematologic control and sustained cytogenetic remission with imatinib monotherapy 85 or treatment with SU11657, an experimental agent that also inhibits PDGF signalling. 86 
FLUORESCENT IN SITU HYBRIDIZATION
Although conventional cytogenetic analysis remains the standard for purposes of diagnosis and prognosis in MDS, interest is increasing in the application of more sensitive techniques such as FISH. Reviews of FISH applications in hematologic malignancies have been published recently.
27,87 Briefly, FISH involves hybridization of patient genetic material with a fluorescently labelled DNA probe designed to anneal either to specific DNA sequences or to chromosomal features such as centromeres. The advantages of FISH include its applicability to either peripheral blood or bone marrow, the opportunity to analyze interphase cells instead of only dividing cells, and the capacity to analyze substantially more cells than is possible by conventional cytogenetic analysis. When chromosomal rearrangements are present in only a small subset of neoplastic cells, a common situation in MDS, FISH can offer increased sensitivity over conventional cytogenetics. For purposes of investigation of specific MDS-associated chromosomal deletions, FISH probes are extremely useful for narrowing the common CDRs, 71, 74, 76, [88] [89] [90] [91] and they can also identify the precise types of cells involved in the neoplastic process. 90, [92] [93] [94] [95] [96] [97] [98] Several groups have developed FISH "panels" that are designed to detect the chromosome abnormalities most commonly identified in patients with MDS, such as those involving chromosomes 5, 7, 8, 11, 13 ). Chromosome aberrations detected only by FISH have not yet been shown to have the same prognostic importance as those revealed by conventional cytogenetics, and thus at present there is no compelling clinical reason to perform FISH at the time of diagnosis of MDS if the karyotype is successful. However, because the critical molecular defect is likely to be the same regardless of how the chromosomal breakpoint is detected, specific high-yield FISH assays will probably be incorporated eventually into prognostic and treatment-response algorithms, 107 as in CML. 26, 108 For example, in the European clinical trial of decitabine for MDS, 2 patients had chromosomal responses detected by FISH that correlated with clinical and cytogenetic response. 59 If standard karyotyping is unsuccessful because of a fibrotic marrow, failure of aspirated cells to grow in culture, or other technical problems, it is reasonable to resort to FISH using a panel designed to detect abnormalities with recognized prognostic relevance. Additionally, in view of the promising recent findings by List et al 24 of a high rate of complete hematologic and cytogenetic response to lenalidomide therapy in patients with MDS with 5q31.1 deletions, it may be especially valuable to perform FISH directed at detection of loss of the CDR on chromosome 5, particularly when the marrow morphologic features suggest 5q-syndrome. Patients with cryptic 5q deletions might then be referred for appropriate clinical trials. Over time, as the presence of other cytogenetic abnormali-ties is correlated with response to novel therapies, the role of specific FISH tests in MDS is likely to expand. (Figure 3) . 109, 110 These methods offer greater sensitivity than conventional karyotyping and are useful for characterizing cryptic chromosomal rearrangements and the origin of structurally ill-defined chromosomal material such as "marker" chromosomes, in which the normal counterpart is not readily identified because of an ambiguous banding pattern.
MULTICOLOR FISH AND SPECTRAL KARYOTYPING
Despite the heightened power of discrimination that M-FISH and SKY technologies may offer, 111 their clinical usefulness in MDS has yet to be proved. For example, in patients with MDS with a normal karyotype by conventional cytogenetics, unrecognized cryptic abnormalities are rarely identified by M-FISH or SKY. 99, 100, 112 In contrast, additional rearrangements are often detected when chromosome painting methods are performed in patients with MDS with abnormal karyotypes 109, 111, [113] [114] [115] [116] ; however, the clinical relevance of these abnormalities is as yet undefined.
COMPARATIVE GENOMIC HYBRIDIZATION
Comparative genomic hybridization (CGH) is a new technique that applies fluorescent hybridization to detect differences in DNA copy number between a patient sample and a normal control, giving insight into loss or gain of chromosomal segments. 117 The ratio of the signal strength from the patient DNA to the reference DNA is measured in each chromosomal region. Until recently, the resolution of CGH was limited and only allowed detection of chromosomal gains or losses of 20 megabase pairs or greater. Despite this, even first-generation CGH probes provided sufficient sensitivity to discover cryptic rearrangements in patients with myeloid diseases including MDS, and soon the resolution had improved to almost 1 megabase pair. 118, 119 Newer array-based CGH methods, including a recently described tiling array that maps the entire human genome with more than 30,000 clones, promise to improve sensitivity sufficient to resolve even minute DNA alterations.
117,120
POINT MUTATIONS IN MDS
Conventional cytogenetic studies and FISH probes detect large chromosomal rearrangements. However, isolated base pair changes or so-called point mutations may also inactivate or result in constitutive gain of function of the affected gene, with important biological consequences.
Discovery of these mutations is one of the major open frontiers in MDS molecular pathology, with initial investigations focusing on recognized tumor suppressor genes.
TP53
The tumor suppressor gene TP53, a critical cell-cycle checkpoint regulator, was the first gene evaluated in MDS because of its high frequency of inactivation in solid tumors. In myeloid malignancies such as MDS and AML, TP53 mutations are uncommon, detected in no more than 15% of patients with primary MDS, with a higher frequency in atomic bomb survivors and patients treated previously with chemotherapy or radiotherapy. [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] Such mutations are generally demonstrable at the time of diagnosis and may have independent prognostic value. 128, 131 Even in tumor types in which TP53 mutations are common, TP53 mutation testing is rarely performed in clinical practice, unless a germline mutation leading to a general cancer susceptibility syndrome (the Li-Fraumeni syndrome) is suspected. This is primarily because patients with TP53-mutant neoplasias have not yet been shown to benefit from differential clinical management. For both inherited and acquired mutations, direct genetic analysis of TP53 by sequencing is required because immunohistochemical results do not correlate well with mutation status. 132, 133 Newer high-throughput technology may change the cost-benefit analysis of TP53 mutation screening and make this assay more accessible to clinicians (although its usefulness remains to be determined). For instance, denaturing high-performance liquid chromatography, which separates wild-type and mutant DNA on the basis of the differential affinity of DNA heteroduplexes and homoduplexes on polystyrene beads coated with a gradient of organic solvents, has shown promise as a more rapid TP53 screening method in MDS and other tumors 134 (D.P.S., unpublished data, 2004).
NRAS AND FLT3
The RAS proto-oncogene superfamily encodes guanosine triphosphate hydrolases (GTPase) that are critical regulators of cellular growth-related signals. Three RAS protooncogenes (H, N, and K) encode four 21-kd G proteins, including 2 alternatively spliced K-Ras products that are posttranslationally modified before incorporation into the inner leaflet of the plasma membrane. RAS mutations occur at critical regulatory sites (eg, codons 12, 13, and 61) that inactivate the GTPase response normally stimulated by the binding of GTPase-activating proteins, thereby extending the half-life and signalling activity of the Ras-GTP bound mutant. In myeloid malignancies, NRAS mutations predominate, especially a common mutation in codon 12; nonetheless, the frequency of activating RAS mutations in unselected cases of MDS is relatively low, ranging from 10% to 15% of MDS. In contrast, in CMML, RAS mutations are found in 40% to 60% of patients and are believed to contribute to growth factor hypersensitivity of myelomonocytic progenitors. 130, [135] [136] [137] [138] [139] Internal tandem duplications and other constitutively activating mutations of the receptor tyrosine kinase FLT3 are common in AML but are relatively rare in MDS. 130, 138, [140] [141] [142] [143] Acquisition of NRAS and/or FLT3 mutations has been associated with progression of MDS to AML. 137, 138, 140 
RUNX1/AML1
The most common point mutations detected in MDS to date are those involving the core-binding-factor subunit RUNX1/AML1. [144] [145] [146] [147] [148] [149] [150] [151] In leukemia, this transcription factor and oncogene is involved in common balanced translocations such as t(8;21), which leads to formation of aberrantly active chimeric fusion proteins and uncontrolled cell growth. Although early reports estimated that RUNX1/ AML1 mutations were rare in MDS, 148 more recent studies have described these mutations in as many as 25% of patients, 150 and single-institution studies have associated RUNX1/AML1 mutation status with chromosome 7q abnormalities, 149 more advanced forms of MDS, 150, 151 and a high risk of progression to overt leukemia. 150, 151 ATRX Specific gene mutations may be associated with unique MDS phenotypes. For instance, the rare complication of acquired α-thalassemia (hemoglobin H disease) arising in the context of MDS was recently linked to mutations in the ATRX gene at Xq13.1. 152, 153 Inherited mutations in ATRX cause a mild form of α-thalassemia and severe syndromic X-linked mental retardation, 154 whereas acquired somatic ATRX mutations create a severe imbalance in globin synthesis, a large proportion of hemoglobin H-containing cells, and the unusual finding of microcytic, hypochromic red cell indices. 152, 153, 155 The distinct behavior of mutations like ATRX when they are acquired in the context of MDS, rather than inherited in the germline, may offer important insights into MDS pathobiology. 155 
MUTATIONS FOUND PREDOMINANTLY IN CMML
In addition to having unique clinical features and unique chromosomal translocations [such as the t(5;12) PDGFRβ-TEL fusion], CMML has several point mutations that appear with great frequency but are uncommon in other MDS subtypes. Patients with CMML have a high frequency of activating RAS mutations and a disproportionately higher frequency of c-FMS point mutations, although the latter are rare overall in myeloid disorders. 156, 157 Likewise, mutations in the protein tyrosine phosphatase gene PTPN11 (which cause a form of Noonan syndrome when inherited) are extremely uncommon in MDS in general, more common in CMML, and especially common (ie, 34% frequency) in the pediatric syndrome juvenile myelomonocytic leukemia, which shares some features with CMML. 158, 159 FIGURE 3. Multiplex fluorescent in situ hybridization (M-FISH) study of a patient with a malignant myeloid disorder. Conventional G-banded cytogenetic analysis (left) was karyotyped as 46,X,t(X;1)(q24;q25),t(6;8)(q25;q24.1),11,13,add(15)(q26),12mar [19] /46,XX [1] .
32 M-FISH analysis confirmed the t(X;1) and t(6;8), identified the 2 markers as der(13)t(11;13), and identified the add(15) as a der (15)t(13;15). In addition, t(9;11)(p21;q23) was detected, involving chromosome 9 and one of the marker chromosomes, and was confirmed as an MLL gene rearrangement. Arrows designate the abnormal chromosomes. Photograph courtesy of Rhett P. Ketterling (Figure 4 ). The frequencies of specific point mutations described previously are likely to be underestimates. Unlike AML, in which the marrow is almost completely replaced by neoplastic cells, blood and marrow in MDS include a heterogeneous mix of neoplastic and residual normal cells, and direct sequencing may be sensitive only to mutant DNA encompassing at least 20% to 30% of the tested sample. Techniques such as denaturing high-performance liquid chromatography, denaturing gradient gel electrophoresis, and polymerase chain reaction-single-strand conformational polymorphism are more sensitive to mosaicism than direct sequencing. 153, [160] [161] [162] In addition, for a more accurate estimate of mutation frequency, it is important not only to assay genes of interest at the genomic DNA (gDNA) level but also the gene message since messenger RNA splicing variants are common causes of human disease. 163 Mutations that affect splicing can be missed if sequencing of gDNA is limited only to the coding region (exons) because splicing abnormalities frequently arise from mutations residing in introns, both within the consensus splice donor and acceptor sites and outside of these areas (ie, in intronic splice enhancer or inhibitor sites). In the case of ATRX, patients with MDS with clonally restricted splicing abnormalities predicted to result in loss of critical ATRX protein domains have been described, but in all of these cases the causative mutation has not yet been identified at the gDNA level. 155, 164 A mutation in a cryptic splice enhancer or inhibitor element at some distance from the site of the splicing abnormality is likely responsible. The expensive and time-consuming search for splicing mutations and missense mutations as well as the need to use a technique sensitive to mosaicism illustrates why point mutation detection in MDS has not yet become mainstream.
MITOCHONDRIAL GENE MUTATIONS IN MDS
A recent report of mutations in the mitochondrial genome in patients with MDS, including frequent mutations in the cytochrome-c oxidase genes, generated some excitement because it offered an alternative genomic source potentially contributing to the MDS phenotype. 165 Mitochondria are a logical target for MDS mutation analysis, given the presence of ringed sideroblasts-pathological iron-laden mitochondria-in many patients, which suggests a possible common metabolic disturbance in mitochondrial enzymes such as cytochrome. 166 Mitochondrial enzymes are encoded by both the 16.6 kilobase pair mitochondrial genome and the nuclear genome. However, another group of investigators sequenced the entire mitochondrial genome in 10 patients with MDS and were unable to reproduce the findings. 167 Several amino acid changes were found in patients but not controls, but the investigators suggested that this might be a reflection of limited clonality among hematopoietic stem cells rather than an indication of mitochondrial genome instability. 167 Subsequently, a novel somatic mutation of mitochondrial transfer RNA was detected in a patient with MDS, 168 and work continues in this area.
FUNCTIONAL IMPORTANCE OF POINT MUTATIONS IN MDS
In each of the genetic mutations described previously, functional consequences arise from modification of the protein encoded. For instance, RUNX1/AML1 point mutations alter DNA binding and transactivating potential of the mutant RUNX1/AML1. 147 In light of the inherent genomic instability in MDS, "innocent bystander" mutations, ie, those with no known functional consequence, may occur with equal or greater frequency. Patients with MDS sometimes have clonally restricted gene mutations that do not result in amino acid substitutions and have no obvious effect on transcript splicing (Figure 4) . If there is no detrimental effect on cell survival, darwinian pressure in the marrow will not select against hematopoietic clones bearing this class of mutation. ATRX mutations may be an example of a neutral mutation with a readily discernible phenotype (ie, defective α globin production in red cells). 153, 155 A vast number of point mutations likely await discovery in MDS. The task of determining which of these are important in the pathobiology of the disease will be challenging.
GENE EXPRESSION PROFILING
A gene need not be altered structurally to modify its expression and affect normal cellular homeostasis. One of the principal ways in which gene expression can be altered is through epigenetic modification, including changes in the way DNA and its associated histones are packaged into chromatin, and, as a consequence, the accessibility of that DNA for transcription. The term epigenetic refers to heri-
GENETIC TESTING IN THE MYELODYSPLASTIC SYNDROMES
Patient's blood
Patient-derived lymphoblastoid cell line
Wild-type blood FIGURE 4. Analysis of exon 6 of GATA1 in archival blood and marrow samples from a group of patients with myelodysplastic syndromes. Top, Chromatogram from denaturing highperformance liquid chromatography Transgenomic WAVE mutation detection system. Most patient samples exhibit only a single peak from homoduplexed wild-type DNA (right peak), but DNA derived from a peripheral blood buffy coat from one patient exhibits a second peak (left peak, arrow), indicating the presence of a DNA heteroduplex formed from a mix of wildtype and mutant DNA. Bottom, Sequencing of the patient's GATA1 gene revealed an acquired c.1066C>T mutation (described in terms of Genbank Accession NM_002049.2) (arrow), which was not present in DNA derived from an Epstein-Barr virus-transformed lymphoblastoid cell line from the patient or from DNA derived from a wild-type (normal) individual. Surprisingly, this clonally restricted mutation did not obviously result in an amino acid change. RNA was unavailable to determine whether the mutation might affect splicing.
table alterations in the pattern of gene expression that are not a consequence of changes in the nucleotide sequence of a gene. 169 Such changes are of interest in cancer, in part because abnormal epigenetic silencing of genes has been shown to be associated with neoplasia development and progression. 170 For instance, 5′ methylation of cytosine nucleotides in the promoter region of tumor suppressor genes can lead to silencing of those genes. 171 In MDS, the first gene found to be commonly hypermethylated and silenced was the P15INK4B gene that encodes a cyclindependent kinase inhibitor. [172] [173] [174] [175] [176] [177] Methylation silencing of p15 is rare in patients with low leukemic cell burden; however, it is detected in more than 75% of cases with excess blasts and occurs uniformly with AML transformation, suggesting a pathogenetic role in disease progression. Epigenetic gene silencing in human neoplasia has swiftly gained importance as a therapeutic target because of its potential reversibility with pharmacological agents. 169, 178 The clinically beneficial nucleoside analogue 5-azacitidine has dual therapeutic effects resulting from direct cytotoxicity as a nucleoside analogue and from inhibition of genomic methylation. 12, 179 Treatment with decitabine, the active metabolite of 5-azacitidine, has been associated with demethylation of hypermethylated P15INK4B in MDS, al- though not consistently. 179 The addition of histone deacetylase inhibitors and other epigenetic modifiers to demethylating agents holds considerable promise for powerful chromatin remodelling strategies. 180 Until recently, molecular investigations focused on expression of 1 or more genes of interest at a time. For example, in a few patients with MDS with intact TP53 genes (ie, no coding mutation), expression of the gene has been found to be decreased. 181 This down-regulation may result in loss of p53 function with biological consequences equivalent to those resulting from mutational inactivation. The advent of complementary DNA microarray technology offers the ability to survey the expression pattern of thousands of genes concurrently. 182 The results of MDS microarray studies have not yet yielded many pathophysiological insights, although some leads have been generated. [183] [184] [185] [186] For instance, the first ATRX mutation was identified after a microarray study of purified neutrophils showed dramatic down-regulation of the gene compared with normal controls (ultimately found to be the consequence of a point mutation in a consensus splice site). 152 Another group has detected overexpression of DLK1 (Delta-like homolog), a gene of unknown function with homology to epidermal growth factor that was first identified as a regulator of adipocyte differentiation, in patients with MDS but not in patients with AML. 183 If microarray studies finally fulfil their promise, it is hoped that they will lead to more accurate MDS diagnosis, classification, and prognostic discrimination and provide more insight into the disease pathobiology. Recent microarray-generated advancements in the understanding of diffuse large B-cell lymphoma 187 and breast cancer 188 illustrate the tremendous power of this technology.
CONCLUSION
Genetic testing in MDS is currently an essential component of clinical care of patients, and testing options are likely to evolve in the near future. At present, conventional cytogenetic studies remain a critical part of the diagnostic evaluation of MDS, and the results offer valuable prognostic information. Detection of specific MDS-associated point mutations and measurement of gene expression patterns are not yet part of routine clinical care, but they promise to expand clinicians' ability to diagnose, prognosticate, and ultimately treat patients with MDS. 43. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes
